Molecular testing has further enhanced diagnostic precision by enabling the identification of key mutations, including H3K27M, ACVR1 (Activin A Receptor Type 1), and TPS53 (Tumor Protein p53), which contribute to DIPG’s aggressive phenotype [3]. This evidence concerns the gene TP53 and diffuse intrinsic pontine glioma.